Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
Vaxxinity corporate headquarters in Cape Canaveral, Fla. Vaxxinity corporate headquarters in Cape Canaveral, Fla. (Photo: Vaxxinity)CAPE CANAVERAL, Fla., May 09,...
Brain
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results
Lead-in data from Phase 3 PEAK trial to be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual...
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey inhibitor BDTX-1535 in...
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer
Trivehexin radiopharmaceuticals being developed for imaging and treatment of cancers expressing αvβ6-integrinPancreatic ductal adenocarcinoma is primary indication due to high...
Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
SIG-002, Sigilon’s lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of...
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 08, 2023 (GLOBE NEWSWIRE) -- In preclinical studies, PMN310 demonstrated the ability to selectively...
Cerevance to Present at the 2023 RBC Capital Markets Global Healthcare Conference
BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous...
Surgalign Announces Release of HOLO™ AI Insights for Neurovascular Research
New HOLO AI Insights application aims to advance research of neuroanatomy utilizing artificial intelligenceDEERFIELD, Ill., May 08, 2023 (GLOBE NEWSWIRE)...
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter...
NeuroOne® to Present at the Sidoti Micro-Cap Virtual Conference on May 10
EDEN PRAIRIE, Minn., May 05, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a...
Coave Therapeutics Demonstrates its Modified coAAV Vectors Outperform AAV9 to Address Neurological Disorders
New data to be presented at ASGCT 2023 Paris, France, May 4, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology...
Male Plus Is Calming Nerves and Restoring Fun to the Bedroom
The Belgian Health and Wellness Brand’s Natural Libido Enhancer Utilizes Ingredients That Calm the Mind While Revving Up the BodyFort...
NeuroOne® Announces U.S. Commercial Launch of Evo® sEEG Electrodes
Evo sEEGs complementary to Zimmer Biomet’s robotic neurosurgery platform; strong market opportunity for paired technologies EDEN PRAIRIE, Minn., May 02,...
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
Over 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam.Completion of patient enrollment for Phase 3 program still...
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team...
Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
Providence, RI, May 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the...
Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for...
Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma
ERAS-801 has demonstrated broad preclinical activity against oncogenic EGFR variants and wildtype alterations Initial THUNDERBBOLT-1 Phase 1 data in patients...
Pathways to Cures are in Sight as MS Canada Hosts Annual Day on the Hill with Carnation Pinning
OTTAWA, May 01, 2023 (GLOBE NEWSWIRE) -- Dozens of representatives of MS Canada are fanning across Ottawa May 1st – May...
ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023
SOLANA BEACH, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform...